BOXED O
WARNING O
: O
WARNING O
: O
VISION O
LOSS O
WARNING O
: O
VISION O
LOSS O
* O
SABRIL O
causes O
permanent B-OSE_Labeled_AE
bilateral O
concentric O
visual I-OSE_Labeled_AE
field I-OSE_Labeled_AE
constriction I-OSE_Labeled_AE
. O

Because O
assessing O
vision O
may O
be O
difficult O
in O
infants O
and O
children O
, O
the O
frequency O
and O
extent O
of O
vision B-NonOSE_AE
loss I-NonOSE_AE
is O
poorly O
characterized O
in O
these O
patients O
. O

For O
this O
reason O
, O
the O
risk O
described O
below O
is O
primarily O
based O
on O
the O
adult O
experience O
. O

* O
Based O
upon O
adult O
studies O
, O
30 O
percent O
or O
more O
of O
patients O
can O
be O
affected O
, O
ranging O
in O
severity O
from O
mild O
to O
severe O
, O
including O
tunnel B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
to O
within B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
degrees I-OSE_Labeled_AE
of I-OSE_Labeled_AE
visual I-OSE_Labeled_AE
fixation I-OSE_Labeled_AE
, O
and O
can O
result O
in O
disability O
. O

In O
some O
cases O
, O
SABRIL O
also O
can O
damage B-OSE_Labeled_AE
the I-OSE_Labeled_AE
central I-OSE_Labeled_AE
retina I-OSE_Labeled_AE
and O
may O
decrease B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
acuity I-OSE_Labeled_AE
. O

* O
The O
onset O
of O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
from O
SABRIL O
is O
unpredictable O
, O
and O
can O
occur O
within O
weeks O
of O
starting O
treatment O
or O
sooner O
, O
or O
at O
any O
time O
after O
starting O
treatment O
, O
even O
after O
months O
or O
years O
. O

* O
Symptoms O
of O
vision B-NonOSE_AE
loss I-NonOSE_AE
from O
SABRIL O
are O
unlikely O
to O
be O
recognized O
by O
patients O
or O
caregivers O
before O
vision B-NonOSE_AE
loss I-NonOSE_AE
is O
severe O
. O

Vision B-NonOSE_AE
loss I-NonOSE_AE
of O
milder O
severity O
, O
while O
often O
unrecognized O
by O
the O
patient O
or O
caregiver O
, O
can O
still O
adversely O
affect O
function O
. O

* O
The O
risk O
of O
vision B-NonOSE_AE
loss I-NonOSE_AE
increases O
with O
increasing O
dose O
and O
cumulative O
exposure O
, O
but O
there O
is O
no O
dose O
or O
exposure O
known O
to O
be O
free O
of O
risk O
of O
vision B-NonOSE_AE
loss I-NonOSE_AE
. O

* O
Unless O
a O
patient O
is O
formally O
exempted O
from O
periodic O
ophthalmologic O
assessment O
as O
documented O
in O
the O
SHARE O
program O
, O
vision O
should O
be O
assessed O
to O
the O
extent O
possible O
at O
baseline O
( O
no O
later O
than O
4 O
weeks O
after O
starting O
SABRIL O
) O
and O
at O
least O
every O
3 O
months O
during O
therapy O
. O

Vision O
assessment O
is O
also O
required O
about O
3 O
to O
6 O
months O
after O
the O
discontinuation O
of O
SABRIL O
therapy O
. O

* O
Once O
detected O
, O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
due O
to O
SABRIL O
is O
not O
reversible O
. O

It O
is O
expected O
that O
, O
even O
with O
frequent O
monitoring O
, O
some O
patients O
will O
develop O
severe O
vision B-NonOSE_AE
loss I-NonOSE_AE
. O

* O
Drug O
discontinuation O
should O
be O
considered O
, O
balancing O
benefit O
and O
risk O
, O
if O
visual B-NonOSE_AE
loss I-NonOSE_AE
is O
documented O
. O

* O
It O
is O
possible O
that O
vision B-NonOSE_AE
loss I-NonOSE_AE
can O
worsen O
despite O
discontinuation O
of O
SABRIL O
. O

* O
Because O
of O
the O
risk O
of O
visual B-NonOSE_AE
loss I-NonOSE_AE
, O
SABRIL O
should O
be O
withdrawn O
from O
patients O
with O
refractory O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
who O
fail O
to O
show O
substantial O
clinical O
benefit O
within O
3 O
months O
of O
initiation O
and O
within O
2-4 O
weeks O
of O
initiation O
for O
patients O
with O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
, O
or O
sooner O
if O
treatment O
failure O
becomes O
obvious O
. O

Patient O
response O
to O
and O
continued O
need O
for O
SABRIL O
should O
be O
periodically O
reassessed O
. O

* O
SABRIL O
should O
not O
be O
used O
in O
patients O
with O
, O
or O
at O
high O
risk O
of O
, O
other O
types O
of O
irreversible B-Not_AE_Candidate
vision I-Not_AE_Candidate
loss I-Not_AE_Candidate
unless O
the O
benefits O
of O
treatment O
clearly O
outweigh O
the O
risks O
. O

The O
interaction O
of O
other O
types O
of O
irreversible B-Not_AE_Candidate
vision I-Not_AE_Candidate
damage I-Not_AE_Candidate
with O
vision B-NonOSE_AE
damage I-NonOSE_AE
from O
SABRIL O
has O
not O
been O
well-characterized O
, O
but O
is O
likely O
adverse O
. O

* O
SABRIL O
should O
not O
be O
used O
with O
other O
drugs O
associated O
with O
serious O
adverse B-NonOSE_AE
ophthalmic I-NonOSE_AE
effects I-NonOSE_AE
such O
as O
retinopathy B-NonOSE_AE
or O
glaucoma B-NonOSE_AE
unless O
the O
benefits O
clearly O
outweigh O
the O
risks O
. O

* O
The O
possibility O
that O
vision B-NonOSE_AE
loss I-NonOSE_AE
from O
SABRIL O
may O
be O
more O
common O
, O
more O
severe O
or O
have O
more O
severe O
functional O
consequences O
in O
infants O
and O
children O
than O
in O
adults O
can O
not O
be O
excluded O
. O

* O
The O
lowest O
dose O
and O
shortest O
exposure O
to O
SABRIL O
consistent O
with O
clinical O
objectives O
should O
be O
used O
. O

Because O
of O
the O
risk O
of O
permanent B-NonOSE_AE
vision I-NonOSE_AE
loss I-NonOSE_AE
, O
SABRIL O
is O
available O
only O
through O
a O
restricted O
program O
under O
a O
Risk O
Evaluation O
and O
Mitigation O
Strategy O
( O
REMS O
) O
called O
the O
SHARE O
Program O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Further O
information O
is O
available O
at O
[ O
www.sabril.net O
or O
1-888-45-SHARE O
] O
. O

EXCERPT O
: O
WARNING O
: O
VISION O
LOSS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
SABRIL O
causes O
progressive O
and O
permanent O
bilateral O
concentric O
visual O
field O
constriction O
in O
a O
high O
percentage O
of O
patients O
. O

In O
some O
cases O
, O
SABRIL O
may O
also O
reduce O
visual O
acuity O
( O
5.1 O
) O
. O

* O
Risk O
increases O
with O
total O
dose O
and O
duration O
of O
use O
, O
but O
no O
exposure O
to O
SABRIL O
is O
known O
that O
is O
free O
of O
risk O
of O
vision O
loss O
( O
5.1 O
) O
. O

* O
Risk O
of O
new O
and O
worsening O
vision O
loss O
continues O
as O
long O
as O
SABRIL O
is O
used O
, O
and O
possibly O
after O
discontinuing O
SABRIL O
( O
5.1 O
) O
. O

* O
Unless O
a O
patient O
is O
formally O
exempted O
, O
periodic O
vision O
assessment O
is O
required O
for O
patients O
on O
SABRIL O
. O

However O
, O
this O
assessment O
can O
not O
always O
prevent O
vision O
damage O
( O
5.1 O
) O
. O

* O
SABRIL O
can O
cause O
permanent O
vision O
loss O
. O

SABRIL O
is O
available O
only O
through O
a O
restricted O
program O
called O
the O
SHARE O
Program O
( O
5.2 O
) O
. O

